This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Fosamax (and Fosamax Plus D)
Merck & Co., Inc.
Drug Names(s): Alendronate sodium (and alendronate sodium/cholecalciferol); Adrovance (France); Fosavance (EU); Bonalon (Japan), MK-0217, Fosamac, Vantavo
Description: Fosamax is a bisphosphonate that inhibits osteoclast-mediated bone resorption and modulates bone metabolism. Thus, it reduces bone turnover, improves bone mineralization, and increases bone mass. It is taken daily or weekly.
Fosamax Plus D includes cholecalciferol (vitamin D3), which after conversion to 1,25-dihydroxyvitamin D3 increases intestinal absorption of both calcium and phosphate, and is involved in the regulation of serum calcium, renalcalcium and phosphate excretion, bone formation and bone resorption.
Revenue splits for this drug are BMT estimates.
In January 2007, Ipsen and Merck Sharp & Dohme (MSD), announced the signing of a co-marketing agreement under which MSD will grant Ipsen themarketing rights in France for Adrovance. Under the terms of the agreement, Ipsen will source the product from MSD, market and sell itunder the brand name Adrovance in France.
Partners: Ipsen SA Teijin Pharma Limited
Fosamax (and Fosamax Plus D) News
Additional information available to subscribers only: